Association Between Statin Use Prior to Admission and Lower Coronavirus Disease 2019 (COVID-19) Severity in Patients With Cardiovascular Disease or Risk Factors.

Abstract

BACKGROUND:

Cardiovascular diseases and/or risk factors (CVDRF) have been reported as risk factors for severe coronavirus disease 2019 (COVID-19).Methods and Results:In total, we selected 693 patients with CVDRF from the CLAVIS-COVID database of 1,518 cases in Japan. The mean age was 68 years (35% females). Statin use was reported by 31% patients at admission. Statin users exhibited lower incidence of extracorporeal membrane oxygenation (ECMO) insertion (1.4% vs. 4.6%, odds ratio [OR]: 0.295, P=0.037) and septic shock (1.4% vs. 6.5%, OR: 0.205, P=0.004) despite having more comorbidities such as diabetes mellitus.

CONCLUSIONS:

This study suggests the potential benefits of statins use against COVID-19.

• Authors: Yuji Ikari, Yuya Matsue, Sho Torii, Misaki Hasegawa, Kazuki Aihara, Shunsuke Kuroda, Takahide Sano, Takeshi Kitai, Taishi Yonetsu, Shun Kohsaka, Takuya Kishi, Issei Komuro, Ken-Ichi Hirata, Koichi Node, Shingo Matsumoto
• Journal: Circulation journal : official journal of the Japanese Circulation Society (Circ J) Vol. 85 Issue 6 Pg. 939-943 (05 25 2021) ISSN: 1347-4820 [Electronic] Japan
• PMID: 33952833 (Publication Type: Journal Article, Multicenter Study)

Chemical References

• Hydroxymethylglutaryl-CoA Reductase Inhibitors

Topics

• Aged
• Aged, 80 and over
• COVID-19 (diagnosis, epidemiology, therapy)
• Cardiovascular Diseases (diagnosis, drug therapy, epidemiology)
• Comorbidity
• Databases, Factual
• Dyslipidemias (diagnosis, drug therapy, epidemiology)
• Female
• Heart Disease Risk Factors
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
• Japan (epidemiology)
• Male
• Middle Aged
• Patient Admission
• Retrospective Studies
• Risk Assessment
• Severity of Illness Index
• Time Factors